Thank you for posting these references. I have just read the first one cited, which says PPIs are generally considered safe for long-term treatment, but also states: "There is no evidence that acid suppression therapy with PPIs causes regression of Barrett's esophagus or prevents progression to adenocarcinoma of the esophagus." In light of this, and in view of the fact that PPIs treat symptoms, do not cure, and are of limited efficacy, it is difficult for us poor patients to evaluate risks versus benefits. The article does warn that PPIs may inhibit absorption of certain drugs, as well as B-12 and iron, which sounds like a bit of a risk to me.
Interesting that the article mentions that the most frequent adverse effects are "headache, diarrhea, abdominal pain and nausea." (Of course the drug companies also acknowledge a very long list of possible side effects, much more serious.) Just like the side effects once listed for Propulsid -- headache, diarrhea, abdominal pain, constipation and nausea. The FDA approved Propulsid in 1993, apparently believing that it carried only minor risks. Presumably that drug had been the subject of a number of scientific trials. It wasn't recalled until 2000.
It would be interesting to know where the funding is coming from for research on GERD-related drugs. (No funding source is given for the article in question.) It would also be interesting to find a few more studies on non-drug alternatives for GERD therapy. And studies on the cause of the condition. But who would fund them? Not the rich drug companies, unfortunately.
Seagal